Cholera and Guillain–Barré Syndrome: When Epidemics Trigger Autoimmune Neuropathy

In regions affected by recurrent cholera outbreaks, overlapping infectious diseases can obscure the diagnosis of post-infectious autoimmune conditions. We recently collaborated in the publication describing a pediatric case from Yemen that illustrates how Guillain–Barré Syndrome (GBS) can emerge during a cholera outbreak, highlighting the critical role of Campylobacter jejuni infection and anti-ganglioside antibody testing ¹.

Guillain–Barré syndrome as a post-infectious complication

Guillain–Barré Syndrome as a Post-Infectious Complication Guillain–Barré Syndrome is an acute immune-mediated polyradiculoneuropathy and a leading cause of acute flaccid paralysis worldwide. It is most frequently triggered by gastrointestinal infections, particularly C. jejuni (see also the Guillain-Barré syndrome outbreak in Pune, India).

The symptoms manifest initially as sensory disturbances and progressive limb weakness, with the potential to evolve into respiratory failure without correct treatment. Mortality and long-term disability largely depend on early recognition, access to intensive care, and immunotherapy such as intravenous immunoglobulin (IVIG).

Case Context: Guillain–Barré Syndrome During a Cholera Outbreak in Yemen

The reported case involved a 12-year-old boy who developed rapidly progressive paralysis following acute watery diarrhoea consistent with cholera. The epidemiological setting -an active cholera outbreak in rural Southern Yemen- initially complicated the diagnostic pathway.

Despite limited local resources, nerve conduction studies and cerebrospinal fluid analysis supported a diagnosis of GBS. Medipan & GA Generic Assays were involved in an international laboratory collaboration that allowed for advanced serological testing. This testing confirmed previous exposure to C. jejuni and strong anti-GD1b IgG positivity.

Campylobacter jejuni, Molecular Mimicry, and Anti-Ganglioside Antibodies

The association between C. jejuni and Guillain-Barré syndrome (GBS) is attributed to a process known as molecular mimicry. In this mechanism, bacterial lipooligosaccharides exhibit a structural similarity to neuronal gangliosides, leading to the production of cross-reactive autoantibodies. Anti-ganglioside antibodies -such as anti-GD1b, GM1, and GD1a- are key biomarkers of immune-mediated nerve injury. Several other pathogens have been suggested to be associated with the development of GBS, probably via a similar mechanism. These include Mycoplasma pneumoniae, cytomegalovirus, Epstein–Barr virus, hepatitis A virus, influenza A and B viruses, and newly emerging infectious diseases such as Zika virus and SARS-CoV-2 ².

Clinical Implications in Cholera and Guillain–Barré Syndrome

Clinical Implications in Cholera and Guillain–Barré Syndrome The pathogenic bacterium Vibrio cholerae, which causes the deadly disease cholera, is not known to directly trigger Guillain-Barré syndrome (GBS). However, concurrent enteric infections during cholera outbreaks may modulate immune responses and increase the risk of autoimmune neurological complications. This case reinforces several key points:

• GBS should be considered during cholera outbreaks when acute neurological symptoms appear
• Anti-ganglioside antibody testing provides valuable immunological confirmation
• Early IVIG treatment and rehabilitation significantly improve outcomes
• International diagnostic collaboration can overcome local resource limitations

Products used in the study

Other Gangliosides Related products

References:

1. Nasser et al., (2025) Post-Infectious GBS During a Cholera Outbreak in Yemen-A Paediatric Case with Confirmed Campylobacter Exposure ↩︎
2. Koike et al., (2021) Emerging Infection, Vaccination, and Guillain-Barré Syndrome: A Review ↩︎